Co-Diagnostics Inc. (NASDAQ:CODX) changes shares on Monday trading session, with a change of 11.88% or $1.85 shares. The trading starts at $15.40 and closed at $15.57 throughout the day. The trading session low price was $15.40 and day high was $17.88 on Monday, June 15. After the session, the Healthcare sector daily volume shifted to 3.96 million while its average volume is 7.38M. In other hand, the CODX market cap reached to $470.51M. While, its current target price is $17.42 according to WSJ.
Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is up 8.88% and down -21.28% for month. Its quarterly performance was 91.64% above, while its half year performance is up 1668.53%. CODX yearly performance stood at positive 2051.68% and rise 1845.93% for year-to-date. Current recommendation for Co-Diagnostics Inc. is 2.00.
Earnings per share or EPS is an important financial measure, which defines the profitability of a company. CODX EPS (TTM) for 12-month is -0.33. EPS for this year is 26.40%, while for the next year its value is 2.05. Its EPS Q/Q reached 45.20%. It has an EPS of -22.60% down for past five years.
Let’s take a look on the analyst recommendations on CODX for the current month and previous month. For the current month, 3 of 3 analysts recommend stock as Buy while 0 as Sell, 0 as overweight, 0 as underweight and 0 as Hold. As compared with the previous month ratings, 0 analysts participate in stock recommendation. Out of 0, 0 rated it sell, 0 rated it as Buy and 0 as Hold Ratings. On the other hand, target price ranges from $30.00-$36.00. Average target price for CODX was reached at $33.67.
Vanguard Group, Inc. (The), Morgan Stanley and Geode Capital Management, LLC are the top three holders in Co-Diagnostics Inc. (CODX) stock. On Mar 30, 2020, Vanguard Group, Inc. (The) has 0.78 million shares which valued 5.92 million. On Mar 30, 2020, Morgan Stanley owned 0.37 million shares which valued at 2.8 million. On Mar 30, 2020, Geode Capital Management, LLC has a total of 0.12 million shares which valued at 0.92 million. In the end, Geode Capital Management, LLC have 0.44% shares outstanding of Co-Diagnostics Inc. (CODX) on Mar 30, 2020. The insider ownership moved to 24.21% and institutional holding shifted to 13.10%.
The company posted an EPS (TTM) of -0.33. According to the most recent quarter report on (Jun 2020), 3 analysts estimated an average EPS of 0.59, while -0.08 EPS posted a year ago period. Analyst Estimated EPS for CODX published in the report was 0.46-0.69 during the same period. Comparing with last year, the average estimated EPS was -0.08 which is lower than -0.05 which was posted for recent quarter EPS.
A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for CODX rise 191.68% for period of 200 days. SMA for 50 days was 17.58% which is showing green signal, while SMA-20 was 1.28%. The moving average value for Co-Diagnostics Inc. (CODX) is 8.42 and 16.54 for 200 and 50 days respectively.
Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in CODX stock. On May 28, SERBIN RICHARD S, Director, sold 25,000 trading shares at the cost of $18.02, which valued at 0.45 million. On May 26, Durenard Eugene, Director, sold 25,000 shares at the cost of $18.26, with total shares of 0. On May 20, Durenard Eugene, Director, sold 25,000 shares at the cost of 18.40. After this transaction, Durenard Eugene total shares reached to 0 which valued at 0.46 million.